BLAKE DRAIN UNKNOWN PRODUCT
Report
- Report Number
- 2210968-2022-07372
- Event Type
- Injury
- Date Received
- September 8, 2022
- Date of Event
- September 27, 2021
- Report Date
- September 8, 2022
- Manufacturer
- ETHICON INC.
- Product Code
- GBX
- PMA / PMN Number
- CL I EXEMPT
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- UK
- Reporter Occupation
- OTHER
Narratives
PRODUCT COMPLAINT # (B)(4). (B)(4). ADDITIONAL INFORMATION HAS BEEN REQUESTED HOWEVER NOT RECEIVED TO DATE. IF FURTHER DETAILS ARE RECEIVED AT A LATER DATE A SUPPLEMENTAL MEDWATCH WILL BE SENT. WERE THE CASES DISCUSSED IN THIS ARTICLE PREVIOUSLY REPORTED TO ETHICON? IF YES, PLEASE PROVIDE A COMPLAINT REFERENCE NUMBER. DOES THE SURGEON BELIEVE THAT ANY OF THE ETHICON PRODUCTS INVOLVED: 15 FR BLAKE DRAIN CAUSED AND/OR CONTRIBUTED TO THE POST-OPERATIVE COMPLICATIONS: INFECTION, SEROMA, SKIN NECROSIS, CELLULITIS, DESCRIBED IN THE ARTICLE? DOES THE SURGEON BELIEVE THERE WAS ANY DEFICIENCY WITH ANY OF THE ETHICON PRODUCT 15 FR BLAKE DRAIN USED IN THIS PROCEDURE? IF SO, PLEASE PROVIDE DETAILS. WHICH SPECIFIC ETHICON 15 FR BLAKE DRAIN PRODUCTS HAVE BEEN USED DURING THE PROCEDURES (PRODUCT CODE, LOT NUMBER)? PATIENT DEMOGRAPHICS? THIS REPORT IS RELATED TO A JOURNAL ARTICLE; THEREFORE, NO PRODUCT WILL BE RETURNED FOR ANALYSIS AND THE BATCH HISTORY RECORDS CANNOT BE REVIEWED AS THE LOT NUMBER HAS NOT BEEN PROVIDED. THE SINGLE COMPLAINT WAS REPORTED WITH MULTIPLE EVENTS. THERE ARE NO ADDITIONAL DETAILS REGARDING THE ADDITIONAL EVENTS. CITATION CITE: JOURNAL OF PLASTIC, RECONSTRUCTIVE & AESTHETIC SURGERY 75 (2022) 737¿742 HTTPS://DOI.ORG/10.1016/J.BJPS.2021.09.054. THIS REPORT IS BEING SUBMITTED PURSUANT TO THE PROVISIONS OF 21 CFR, PART 803. THIS REPORT MAY BE BASED ON INFORMATION WHICH HAS NOT BEEN INVESTIGATED OR VERIFIED PRIOR TO THE REQUIRED REPORTING DATE. THIS REPORT DOES NOT REFLECT A CONCLUSION BY ETHICON, OR ITS EMPLOYEES THAT THE REPORT CONSTITUTES AN ADMISSION THAT THE PRODUCT, ETHICON, OR ITS EMPLOYEES CAUSED OR CONTRIBUTED TO THE POTENTIAL EVENT DESCRIBED IN THIS REPORT. IF INFORMATION IS OBTAINED THAT WAS NOT AVAILABLE FOR THE INITIAL REPORT, A FOLLOW-UP REPORT WILL BE FILED AS APPROPRIATE.
IT WAS REPORTED VIA JOURNAL ARTICLE: TITLE: INTRODUCING MINIMALLY INVASIVE INGUINAL LYMPH NODE DISSECTION IN A UK TERTIARY SKIN CANCER SERVICE: INITIAL EXPERIENCE & OUTCOMES. THE AIM OF THIS STUDY WAS TO DESCRIBE THE OUTCOMES OF SETTING UP AN MILND SERVICE IN A UK CANCER CENTRE INSIDE A PRESCRIBED CLINICAL GOVERNANCE FRAMEWORK. THIS WAS A RETROSPECTIVE, SINGLE-CENTRE, SINGLE-SURGEON COHORT STUDY. TWENTY-ONE PATIENTS WHO UNDERWENT MILND FROM MAY 2015 TO FEBRUARY 2019 WERE INCLUDED. DEMOGRAPHIC DATA, DISEASE BURDEN, AND SURGICAL QUALITY ASSURANCE PARAMETERS WERE ANALYSED. MEDIAN AGE WAS 69 (IQR: 58¿76) WITH 14 WOMEN (66%) AND 7 MEN (33%). DISSECTION WAS PERFORMED WITH A HARMONIC SCALPEL (HARMONIC ACE®, JOHNSON & JOHNSON, NEW JERSEY, USA) FROM CAUDAL TO CRANIAL. THE DECISION TO LIGATE AND RESECT THE LONG SAPHENOUS VEIN DISTALLY AND AT THE SAPHENOFEMORAL JUNCTION WAS MADE INTRAOPERATIVELY BY THE RESECTING SURGEON BASED ON DISEASE BURDEN AND LOCATION. WHEREVER POSSIBLE, THE SPECIMEN WAS RESECTED EN BLOC AS A SINGLE PACKET. THE CAVITY WAS SUBSEQUENTLY IRRIGATED WITH STERILE WATER AND TWO 15 FRENCH BLAKE DRAINS (ETHICON, INC., NEW JERSEY, USA) WERE INSERTED INTO THE CAVITY PRIOR TO PORT-SITE WOUND CLOSURE. REPORTED COMPLICATIONS INCLUDED INFECTION (N=4), SEROMA (N=1), SKIN NECROSIS (N=1, FEMORAL NERVE PALSY, CELLULITIS IN CONCLUSION WE REPORT THE FIRST UK SERIES OF MILND IN A CUTANEOUS ONCOLOGY SERVICE. OUR RESULTS SHOW THAT MILND IS A SAFE TECHNIQUE THAT CAN BE INTRODUCED INTO A BUSY NHS PRACTICE WITH A STRUCTURED TRAINING PROGRAM, WITH SURGICAL QUALITY ASSURANCE OUTCOMES IDENTICAL TO OPEN INGUINAL LYMPHADENECTOMY. OUR LEARNING CURVE WAS SIMILAR TO PREVIOUSLY PUBLISHED DATA.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 2238407 | BLAKE DRAIN UNKNOWN PRODUCT | CATHETER, IRRIGATION | GBX | ETHICON INC. |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | Unknown | Required Intervention |